This list is an analysis based on recent market events. It's not an investment recommendation.
About
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Show more...
CEO
Mr. Michael R. Minogue
Employees
2003
Country
United States
ISIN
US0036541003
WKN
000873886
Listings
0 Comments
Share your thoughts
FAQ
What is ABIOMED INC ABIOMED ORD SHS stock price today?▼
The current price of 0H7S.LSE is $381.02 USD — it has increased by +0% in the past 24 hours. Watch ABIOMED INC ABIOMED ORD SHS stock price performance more closely on the chart.
What is ABIOMED INC ABIOMED ORD SHS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ABIOMED INC ABIOMED ORD SHS stocks are traded under the ticker 0H7S.LSE.
What is ABIOMED INC ABIOMED ORD SHS revenue for the last year?▼
ABIOMED INC ABIOMED ORD SHS revenue for the last year amounts to 1.03B USD.
What is ABIOMED INC ABIOMED ORD SHS net income for the last year?▼
0H7S.LSE net income for the last year is 136.51M USD.
How many employees does ABIOMED INC ABIOMED ORD SHS have?▼
As of April 21, 2026, the company has 2,003 employees.
In which sector is ABIOMED INC ABIOMED ORD SHS located?▼
ABIOMED INC ABIOMED ORD SHS operates in the Other sector.
When did ABIOMED INC ABIOMED ORD SHS complete a stock split?▼
ABIOMED INC ABIOMED ORD SHS has not had any recent stock splits.
Where is ABIOMED INC ABIOMED ORD SHS headquartered?▼
ABIOMED INC ABIOMED ORD SHS is headquartered in Danvers, United States.